Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Armando Negron Vera

General Practice Hudson, FL Medical Doctor

NPI 1174592695 CMS profile 880409

7463 State Road 52, Hudson, FL 34667

Open in the dashboard

General payments

$170

7 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Armando Negron Vera of Hudson, FL is reported in the CMS Open Payments database as having received $170 across 7 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2023 General $18 1
2021 General $47 3
2019 General $86 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Armando Negron Vera
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Armando Negron Vera were reported at $19. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Armando Negron Vera General Practice median Middle half National median
2019 $86 $107 $37–$285 $163
2020 $0 $75 $25–$213 $114
2021 $47 $93 $30–$272 $132
2022 $0 $103 $36–$279 $149
2023 $18 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $19 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Scilex Pharmaceuticals Inc. $65 1 payment
  2. Janssen Pharmaceuticals, Inc $32 2 payments
  3. Emergent BioSolutions Inc. $20 1 payment
  4. Phadia US Inc. $19 1 payment
  5. Boston Scientific Corporation $18 1 payment
  6. E.R. Squibb & Sons, L.L.C. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $170 7 payments
Products named General payments · program years 2019–2025
  1. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $65 1 payment
  2. XARELTO $32 2 payments
  3. Narcan $20 1 payment
  4. ImmunoCAP $19 1 payment
  5. SpaceOAR VUE System - 10mL $18 1 payment
  6. ELIQUIS $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 131 drugs

Part D claims

7,969

Median for General Practice: 1,105

Drug cost

$273,581

Median for General Practice: $48,734

Branded share of claims

16.4%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 45 $45,135
Januvia Sitagliptin Phosphate Brand 26 $30,184
Xarelto Rivaroxaban Brand 21 $27,171
Jardiance Empagliflozin Brand 14 $20,107
Farxiga Dapagliflozin Propanediol Brand 13 $13,352
Albuterol Sulfate Hfa Albuterol Sulfate Brand 258 $8,073
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 53 $7,029
Breyna Budesonide/Formoterol Fumarate Brand 25 $6,444
Atorvastatin Calcium Generic 766 $5,385
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 39 $5,258

The 10 drugs with the highest cost, of 131 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$3,756

Medicare's payments for the services billed

Medicare patients

27

Average age 74

Services billed

67

16 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 63%
Diabetes 56%
Arthritis 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record